

## ExpreS<sup>2</sup>ion rearranges its event schedule due to Coronavirus restrictions

**ExpreS<sup>2</sup>ion Biotech Holding AB's affiliate ExpreS<sup>2</sup>ion Biotechnologies ApS ("ExpreS<sup>2</sup>ion") is rearranging its recently communicated event schedule due to events changes as a results of COVID-19-related travel restrictions. The company's main priority during this time is to progress rapidly with the ongoing EU Horizon 2020-funded COVID-19 vaccine development project together with the rest of the consortium members.**

ExpreS<sup>2</sup>ion's CEO Bent U. Frandsen will present the company for **the Aktiedagen event on March 16 in Stockholm** virtually, which means you can view it later today at ExpreS<sup>2</sup>ion's website, <https://expres2ionbio.com/investor/presentations/>.

**The BIO-Europe Spring event on March 23-25 in Paris, France** has been transformed into a virtual event, which means that ExpreS<sup>2</sup>ion will be able to participate digitally. This includes conducting online meetings with potential collaboration partners. To pre-arrange business meetings with ExpreS<sup>2</sup>ion representatives, please contact us via email on [info@expres2ionbio.com](mailto:info@expres2ionbio.com). More information at [BIO-Europe's website](#).

**The World Vaccine Congress (WVC), scheduled to take place on April 6-8 in Washington, DC, USA** has been moved to 27-29 September. ExpreS<sup>2</sup>ion is committed to participate at this event in September and discuss its platform and development projects with industry colleagues and potential partners.

### **CEO Bent Frandsen comments**

"Having recently been awarded an EU Horizon 2020-grant for our COVID-19 vaccine development consortium project, progressing rapidly with this project towards clinical trials is of course our top priority at this time. With the digital channels and tools available today, we will be able to continue our day-to-day business as well as planning further ahead even though we will limit our travels for the time being in accordance with restrictions in Denmark and elsewhere."

### **Certified Adviser**

Svensk Kapitalmarknadsgranskning AB  
Telefon: +46 11 32 30 732  
E-post: [ca@skmg.se](mailto:ca@skmg.se)

### **For further information about ExpreS<sup>2</sup>ion Biotech Holding AB, please contact:**

Bent U. Frandsen, CEO  
Telephone: +45 4256 6869  
E-mail: [buf@expres2ionbio.com](mailto:buf@expres2ionbio.com)

### **About ExpreS<sup>2</sup>ion**

ExpreS<sup>2</sup>ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS<sup>2</sup>ion Biotech Holding AB with company register number 559033-3729. ExpreS<sup>2</sup>ion has developed a unique technology platform, ExpreS<sup>2</sup>, for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS<sup>2</sup> is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 300 proteins and 40 virus-like particles (VLPs) in collaboration with leading research institutions and companies. Since 2017, ExpreS<sup>2</sup>ion develops novel VLP based vaccines through its joint venture AdaptVac ApS. For additional information, please visit [www.expres2ionbio.com](http://www.expres2ionbio.com) and [www.adaptvac.com](http://www.adaptvac.com).